Topics:
Genitourinary Cancers • Prostate Cancer • Medical Oncology • Journal Club ft. NEJM publications
For a patient treated with abiraterone for first line metastatic prostate cancer, would you still use a combination of abiraterone/olaparib at a subsequent progression?
If yes, would you directly add olaparib at progression on abiraterone vs waiting to use abi/olaparib at a later line of therapy?
Answer from: Medical Oncologist at Academic Institution
No, there is no evidence for this, and in the absence of benefit, I would use single agent olaparib in HRD+ patients only, particularly BRCA2 patients. Ongoing trials like the CASPAR trial will address this question. In addition, there are ongoing trials testing PARP/AR combinations in men with mHSP...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
This was not the PROpel population – if abiraterone was continued from the metastatic hormone sensitive setting to the metastatic castration resistance setting, I don’t think adding Olaparib directly to abiraterone will salvage the abiraterone resistance.